Literature DB >> 6839074

Growth hormone response to clonidine in obsessive-compulsive patients.

L J Siever, T R Insel, D C Jimerson, C R Lake, T W Uhde, J Aloi, D L Murphy.   

Abstract

We have observed a lesser growth hormone response to intravenous clonidine administration in nine obsessive-compulsive disorder patients meeting research diagnostic criteria than in nine matched controls. The obsessive-compulsive disorder patients had higher plasma free 3-methoxy-4-hydroxyphenylglycol and plasma norepinephrine levels before clonidine than the controls. As blunted growth hormone responses to clonidine are also characteristic of affective disorder patients, these results support other observations of a psychobiologic affinity between these two groups and are also compatible with an association between increased presynaptic noradrenergic activity and decreased post-synaptic receptor responsiveness.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839074     DOI: 10.1192/bjp.142.2.184

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Effects of yohimbine in obsessive compulsive disorder.

Authors:  S A Rasmussen; W K Goodman; S W Woods; G R Heninger; D S Charney
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Effect of sleep deprivation on the growth hormone response to the alpha-3 adrenergic receptor agonist, clonidine, in normal subjects.

Authors:  S Lal; J X Thavundayil; B Krishnan; N P Nair; G Schwartz; M E Kiely; H Guyda
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 3.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

4.  Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder.

Authors:  Daniel Lustberg; Alexa F Iannitelli; Rachel P Tillage; Molly Pruitt; L Cameron Liles; David Weinshenker
Journal:  Psychopharmacology (Berl)       Date:  2020-04-20       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.